(<i>2R,6R</i>)‐hydroxynorketamine prevents opioid abstinence‐related negative affect and stress‐induced reinstatement in mice
These findings emphasize the therapeutic potential of (2R,6R)-HNK, which is currently in Phase II clinical trials, in addressing stress-related opioid responses. Reducing the time and cost required for development of new medications for the treatment of OUDs via drug repurposing is critical due to the opioid crisis we currently face.
Authors
- Andrea Georgiou (ORCID: https://orcid.org/0000-0003-4214-3678)
- Andria Michael (ORCID: https://orcid.org/0009-0009-8193-8423)
- Chris F. Powels (ORCID: https://orcid.org/0000-0003-2483-6884)
- Anna Onisiforou (ORCID: https://orcid.org/0000-0003-3380-7356)
- Elmar Mammadov (ORCID: https://orcid.org/0000-0002-7354-1508)
- Panos Zanos (ORCID: https://orcid.org/0000-0002-1968-8648)
- Polymnia Georgiou (ORCID: https://orcid.org/0000-0003-3171-9993)
- Morfeas Koumas (ORCID: https://orcid.org/0009-0004-3453-5334)
Institutions
- University of Maryland, Baltimore (US)
- University of Cyprus (CY)
- University of Wisconsin–Milwaukee (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1111/bph.70018
- Citations
- 12
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 16.73
Funders
- Brain and Behavior Research Foundation
- IDSA Foundation
- H2020 Marie Skłodowska-Curie Actions